This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Alliance Healthcare continues to defend UK antitrust charges over drug deals (correct*)

By Simon Zekaria ( March 24, 2021, 16:25 GMT | Insight) -- Alliance Healthcare "continues to defend" itself against UK charges of infringing competition law in deals to acquire the antibiotic Nitrofurantoin, according to a US securities filing submitted by AmerisourceBergen, which plans to buy Alliance. Seller Walgreens Boots Alliance said* that the business had “responded in detail to the allegations” from the Competition and Markets Authority, but that a fine was still possible.Alliance Healthcare "continues to defend" itself against UK charges of infringing competition law in deals to acquire the antibiotic Nitrofurantoin, according to a US securities filing submitted by AmerisourceBergen, which plans to buy Alliance....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections